Education
About Us
Working with TipRanks
Follow Us
Alnylam Pharmaceuticals (ALNY)
NASDAQ:ALNY
ALNY Stock Chart & Stats
Day’s Range― - ―
52-Week Range$141.98 - $304.39
Previous CloseN/A
Volume78.96K
Average Volume (3M)897.75K
Market Cap
$34.10B
Enterprise Value$30.43B
Total Cash (Recent Filing)$114.95M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.10
Next Earnings
May 01, 2025EPS Estimate
-0.9Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.17
Shares Outstanding130,084,850
10 Day Avg. Volume1,234,946
30 Day Avg. Volume897,747
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)16.32
Price to Cash Flow (P/CF)-96.90
P/FCF Ratio0.00
Enterprise Value/Market Cap0.89
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit15.81
Enterprise Value/Ebitda-157.66
Forecast
1Y Price Target
$323.33Price Target Upside37.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering22
---
Bulls Say, Bears Say
Bulls Say
FDA ApprovalFDA approval of Alnylam's Qfitlia for Hemophilia A or B patients provides a significant milestone for the company.
Market PositioningAMVUTTRA’s U.S. approval in ATTR-CM represents a pivotal financial inflection point, enabling the achievement of sustainable non-GAAP profitability.
Bears Say
Competitive DynamicsQfitlia is likely to remain a niche product given the challenging competitive dynamics in hemophilia.
Safety ConcernsThe boxed warning for thrombotic events and gallbladder disease represents a meaningful headwind to adoption in a crowded market.
---
Ownership Overview
0.38% Insiders
49.21% Mutual Funds
0.14% Other Institutional Investors
35.14% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ALNY FAQ
What was Alnylam Pharmaceuticals’s price range in the past 12 months?
Alnylam Pharmaceuticals lowest stock price was $141.97 and its highest was $304.39 in the past 12 months.
What is Alnylam Pharmaceuticals’s market cap?
Alnylam Pharmaceuticals’s market cap is $34.10B.
When is Alnylam Pharmaceuticals’s upcoming earnings report date?
Alnylam Pharmaceuticals’s upcoming earnings report date is May 01, 2025 which is in 26 days.
How were Alnylam Pharmaceuticals’s earnings last quarter?
Alnylam Pharmaceuticals released its earnings results on Feb 13, 2025. The company reported -$0.65 earnings per share for the quarter, missing the consensus estimate of -$0.592 by -$0.058.
Is Alnylam Pharmaceuticals overvalued?
According to Wall Street analysts Alnylam Pharmaceuticals’s price is currently Undervalued.
Does Alnylam Pharmaceuticals pay dividends?
Alnylam Pharmaceuticals does not currently pay dividends.
What is Alnylam Pharmaceuticals’s EPS estimate?
Alnylam Pharmaceuticals’s EPS estimate is -0.9.
How many shares outstanding does Alnylam Pharmaceuticals have?
Alnylam Pharmaceuticals has 130,084,850 shares outstanding.
What happened to Alnylam Pharmaceuticals’s price movement after its last earnings report?
Alnylam Pharmaceuticals reported an EPS of -$0.65 in its last earnings report, missing expectations of -$0.592. Following the earnings report the stock price went down -0.402%.
Which hedge fund is a major shareholder of Alnylam Pharmaceuticals?
Currently, no hedge funds are holding shares in ALNY
---
Alnylam Pharma Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$323.33 (37.16% Upside)
$323.33 (37.16% Upside)
Blogger Sentiment
Bullish
ALNY Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Decreased
By 96.5K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.0M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.7%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
73.81%
12-Months-Change
Fundamentals
Return on Equity
-414.62%
Trailing 12-Months
Asset Growth
12.32%
Trailing 12-Months
Company Description
Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
---
ALNY Company Deck
---
ALNY Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflects a positive sentiment with significant revenue growth, profitability, and progress in clinical trials. Despite a slight decline in the rare franchise and anticipated decrease in gross margins, the strong performance and guidance in key areas like the TTR franchise and R&D pipeline suggest a positive outlook.Read More>---
ALNY Revenue Breakdown
67.90% Net product revenues
29.87% Net revenues from collaborations
2.22% Royalty revenue
---
ALNY Stock 12 Month Forecast
Average Price Target
$323.33
▲(37.16% Upside)
Technical Analysis
Best Analysts Covering ALNY
1 Year
1 Year Success Rate
20/30 ratings generated profit
1 Year Average Return
+25.60%
reiterated a buy rating 16 days ago
Copying Ritu Baral's trades and holding each position for 1 Year would result in 66.67% of your transactions generating a profit, with an average return of +25.60% per trade.
---